Sites & Partners

Needham, MA is the home of Invicro’s world headquarters, which includes corporate offices and laboratories to support preclinical imaging and advanced pathology services. Our image analysis and software teams work closely with our multi-discipline research scientists who perform in vivo and ex vivo imaging studies, such as quantitative immunohistochemistry (Q-IHC) and three-dimensional tissue imaging.

Invicro London is a 40,300 square foot purpose-built research facility offering an extensive range of preclinical services and other supporting technologies. These include but are not limited to:

• In vitro/ex vivo characterization of novel tool compounds or drug candidates using IHC, tissue autoradiography, cell binding assays, mass spectroscopy, microscopy and FACS
• High-end radiochemistry services for SPECT, PET, and theranostic applications (ligand, therapeutic, or diagnostic development)
• Proven ability to develop, manufacture, and apply a wide range of PET and SPECT ligands (> 60 tracers available for preclinical use)
• In vivo molecular and anatomical imaging (MRI, CT, US, SPECT, PET, Optical) in a range of neuro, oncology, cardiovascular, and respiratory models
• Ready access to healthy and disease human and animal tissue

Invicro London also leverages its partnership with Queen Mary University of London to access leading radiochemistry and imaging facilities to expand our service capacity and capabilities. The facility has specialized hot labs for synthesis of PET, SPECT, and therapeutic radiochemicals and is fully equipped for radiopharmaceutical development and complimentary in vitro assays and autoradiography analysis. Pre-clinical imaging modalities include SPECT, PET, CT, Optical, Ultrasound, and low-field MRI on rodents, and further in vivo capabilities include animal model development and access to other specialized techniques. Radiochemistry services are provided in partnership with Professor Stephen Mather. For more information on capabilities, please contact enquiries@invicro.co.uk.

Invicro’s New Haven, CT facility has over 70,000 square feet of GCP and GMP compliant research space to support over 150 staff members organized into Clinical, Chemistry, and Core Lab (Imaging Sciences, Project Management, Data Management, Reader Management) Divisions supported by Regulatory and Compliance, Systems Validation, Information Technology, and Business Operations cores. The researchers here execute their work through multiple facilities, including a medicinal chemistry lab for tracer development, cGMP Radiochemistry lab for radioligand production and distribution, on-site PET and SPECT cameras supporting state-of-the-art imaging research, and an image processing and analysis lab focused on advanced analytics for study outcomes.

Co-managed by Invicro and Charles River, the TIC is located on the campus of Charles River Laboratories (CRL) in Mattawan, MI. The TIC represents a combination of integrated imaging solutions offered by comprehensive imaging capabilities in a single location and leveraging the strengths of each partner: Invicro’s molecular imaging informatics team and radiopharmaceutical group and Charles River’s comprehensive CRO services. The world’s first commercially available cyclotron immediately contiguous with on-site vivarium facilities permits drug labeling and tracer synthesis with short-lived isotopes (including C-11, F-18, and I-123) as well as long-lived isotopes (including Cu-64, Zr-89, In-111, I-124, I-125 and many others). All Invicro and CRL staff associated with TIC services excel in the execution of in-depth studies across a wide variety of animal models with industry-leading reporting capabilities and timelines. Capabilities include, but are not limited to all major in vivo imaging modalities: SPECT, PET, MRI, CT, DEXA, X-ray, Laser Doppler, and Ultrasonography. Complementary assays include ex vivo distribution, animal model development and histology, 2D autoradiography, and QWBA, all supported by comprehensive and collaborative scientific expertise and advanced analytics.

Invicro’s state-of-the-art Molecular Imaging Center (MIC) is contained within The Sanford Consortium for Regenerative Medicine (SCRM) in La Jolla, CA. The mission of SCRAM is to advance regenerative medicine research through collaborative, multi-disciplinary interactions. This collaboratortion enables scientists from the La Jolla Institute for Allergy & Immunology, the Salk Institute for Biological Studies, the Sanford Burnham Prebys Medical Discovery Institute, The Scripps Research Institute, and the University of California, San Diego to work side-by-side in a facility specifically designed to achieve breakthrough discoveries. Invicro supports these discoveries and the efforts of pharma and biotech companies through the MIC. The facility includes rodent high field (11.7T) MRI, PET, SPECT, CT, in vivo bioluminescence and fluorescence, and ultrasound. It is structured so that models can be induced within the facility or transferred in.. For tours or additional information please email pmcconville@invicro.com.

Specialized supporting technologies include:

• Focal beam and cabinet irradiators
• BSL2 facility for handling regulated viral agents
• Full spectrum of syngeneic and human cell and PDX tumor models (including orthotopics and metastasis models)

Read more about our full capabilities here

MedChem Imaging designs imaging probes for clients engaged in pharmaceutical research and development. These agents can be radioactive drug candidates or bind targets whose occupancy assists in understanding drug action. MedChem Imaging also supplies specialty materials to the radiopharmaceutical industry.